Global site navigation

AstraZeneca withdraws Covid vaccine as demand dives
Economy

AstraZeneca withdraws Covid vaccine as demand dives

by  AFP 2 min read
AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020
AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020. Photo: Saeed KHAN / AFP/File
Source: AFP

PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app!

Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in demand.

"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied," an AstraZeneca spokesperson added in a statement.

"We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic."

AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020.

Vaxzevria, developed alongside Oxford University, was at first offered at cost but Astra decided in late 2021 to sell it for profit.

Read also

Chinese mill blamed for turning Serbia village red with pollution

But the world pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer and German peer BioNTech, after rare blood-clot problems with Astra's jab increased public hesitancy about taking it.

PAY ATTENTION: Click “See First” under the “Following” tab to see Briefly News on your News Feed!

Sales collapsed further as global Covid restrictions were fully lifted worldwide and the world emerged from the global health crisis.

The AstraZeneca spokesperson said the group had begun the process from taking it off the market in the Europe, Middle East and Africa (EMA) region.

The company will work with other regulators globally to start market authorisation withdrawals for the Vaxzevria "where no future commercial demand for the vaccine is expected".

The spokesperson said that, according to independent estimates, "over 6.5 million lives were saved in the first year of use alone" and more than three billion doses were supplied globally.

Read also

SAMA warns against Covid-19 misinformation, urges caution during flu season

"We are incredibly proud of the role Vaxzevria played in ending the global pandemic," the spokesperson said.

"Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic. "

PAY ATTENTION: Follow Briefly News on Twitter and never miss the hottest topics! Find us at @brieflyza!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Hot: